Biotechnology
Saudi Arabia and France Strengthen Health Cooperation Through Strategic Agreements in Biotech and Digital Health
PARIS, April 17, 2025 /PRNewswire/ -- On the second day of an official visit to France, His Excellency Fahad Abdulrahman AlJalajel, Minister of Health of the Kingdom of Saudi Arabia, held bilateral meetings with senior French officials including Minister for Labour, Health, Solidarity and Familie...
2025-04-17 06:21
3064
Terumo Health Outcomes Now Offers FDA-Cleared Medis QFR® 3.0 Software for Coronary Physiology Assessment in the US
– Innovative AI software supports hospital adoption of advanced tools to improve cath lab workflow and patient comfort – SOMERSET, N.J., April 16, 2025 /PRNewswire/ -- Terumo Health Outcomes (THO), a division of Terumo Interventional Systems (TIS), today announced that Medis QFR 3.0, an FDA-cle...
2025-04-17 01:10
2929
Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights
SHANGHAI, April 16, 2025 /PRNewswire/ -- Henlius (2696.HK) held its 2025 Global R&D Day under the theme of "Collaborate to Create". Senior executives from Henlius gathered with leading experts, scholars, and heads of innovation from across the industry to engage in in-depth discussions on the lat...
2025-04-16 23:30
3118
Putting Patients First, Co-Creating a Bright Future for Human Health: Henlius Releases 2024 ESG Report
SHANGHAI, April 16, 2025 /PRNewswire/ -- On April 15, 2025, Henlius (2696.HK) released the "2024 Environmental, Social, and Governance (ESG) Report" (hereinafter referred to as the "ESG Report" or "Report"). This marks the sixth consecutive year that the company has submitted an ESG-related repor...
2025-04-16 23:22
2700
The Lancet Child & Adolescent Health Publishes Phase III Trial and 24-Month Follow-Up Results of Ziresovir for RSV in Infants Under 6 Months
SHANGHAI, April 16, 2025 /PRNewswire/ -- The Lancet Child & Adolescent Health, a leading international journal in pediatric and adolescent medicine, has published the Phase III clinical trial results ofziresovir, a novel RSV-targeted antiviral drug developed by Shanghai Ark Biopharmaceutical Ltd....
2025-04-16 09:00
3113
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131 I-iodofalan[1]) in recurrent high-grade glioma (brain cancer), substan...
2025-04-16 06:45
2400
SECuRE trial update: First patient treated in the Phase II Cohort Expansion
HIGHLIGHTS * The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of the SECuRE trial has been treated with their first dose of 8 GBq of67Cu-SAR-bisPSMA.This follows the recent recommendation by the Safety Review Committee (SRC) after the successful completion of t...
2025-04-15 21:02
2220
Pilatus Biosciences to Present Research on PLT012 at AACR 2025
Novel Immunometabolism Approach Targets Immune-Cold Solid Tumors DOVER, Del. and EPALINGES, Switzerland, April 15, 2025 /PRNewswire/ -- Pilatus Biosciences, pioneering biologics targeting metabolic checkpoints, will present new research on its lead candidate, PLT012, at the American Association ...
2025-04-15 20:35
1735
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials
KYOTO, Japan, April 15, 2025 /PRNewswire/ -- Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters:Boston, MA;...
2025-04-15 13:20
2073
Covation Biomaterials Announces Launch of BioPTMEG at Chinaplas 2025
SHENZHEN, China, April 14, 2025 /PRNewswire/ -- Covation Biomaterials LLC ("CovationBio®"), a biomaterials company with advanced technology in the bio-based materials industry, proudly announces its newest innovation, CovationBio® bioPTMEG, the advanced, sustainable polytetramethylene ether glyc...
2025-04-14 23:44
2654
Chromatin Bioscience Signs Collaboration Agreement with Astellas
EDINBURGH, Scotland, April 14, 2025 /PRNewswire/ -- Chromatin Bioscience, a
leader in the design of synthetic promoters and gene control systems, is
pleased to announce a collaboration agreement with Astellas Pharma
2025-04-14 17:00
2637
PRISM BioLab and Elix Join Forces to Accelerate AI-Driven Drug Discovery for Protein-Protein Interaction Targets
Strategic Partnership Aims to Create Novel Drug Discovery Pipeline for Unmet Medical Needs by Combining PPI Control Technology with AI Drug Discovery Platform TOKYO, April 14, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM BioLab"), a leading discovery and development biotechnology company ...
2025-04-14 15:00
2311
MGI Tech Celebrates 10 Years of DNBSEQ™ Technology: Driving Genomics Forward with Speed, Scale, and Accessibility
SHENZHEN, China, April 13, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a
company committed to building core tools and technologies that drive innovation
in life science, proudly marks a decade since the commercialization of its
proprietaryDNBSEQ™ sequencing technology
2025-04-14 10:53
2584
Fangzhou Presents AI-Driven Healthcare Ecosystem at Guangzhou Biotech Innovation Salon
GUANGZHOU, China, April 13, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leading Internet healthcare solution provider, participated in the "AI Empowers Biopharma" exchange panel hosted by the Guangzhou Development District Talent Education Group onApril 3, 2025,...
2025-04-14 09:32
2095
Clinical research results for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) published in Nature Medicine, a top international medical journal
CHENGDU, China, April 12, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from a Phase 3 registrational clinical study evaluating the novel TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) for the treatment o...
2025-04-12 17:20
4289
Global First Engineered Exosome with INCI Name -- ImmVira Leads a New Era in International Cosmetic Ingredients
SUZHOU, China, April 10, 2025 /PRNewswire/ -- EonveLab, a subsidiary of ImmVira Group ("ImmVira," or the "Company"), recently announced that its in-house developed engineered exosome product, MVR-EX103, developed for treating superficial skin depressions, has successfully passed the review of th...
2025-04-11 13:19
3079
Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer
CAMBRIDGE, Mass., April 10, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM), ranging from target validation and antibody discovery through preclinical research, today announced a research collaboration with Atossa ...
2025-04-10 20:00
2554
Belief BioMed and Takeda China jointly announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved
SHANGHAI, April 10, 2025 /PRNewswire/ -- Belief BioMed ("BBM") and Takeda China today jointly announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with mod...
2025-04-10 19:23
3616
Angel Yeast Delivers Critical Aid to Myanmar Earthquake Victims, Reinforcing Commitment to Global Humanitarian Efforts
YANGON, Myanmar, April 10, 2025 /PRNewswire/ -- In rapid response to Myanmar's catastrophic 7.9-magnitude earthquake, Angel Yeast Co., Ltd. has mobilized emergency relief supplies through the Myanmar Chinese Chamber of Commerce. This decisive action placesAngel Yeast at the forefront of first res...
2025-04-10 16:24
2970
VCI BIOFUELS GROUP SIGNS DEFINITIVE MERGER AGREEMENT WITH INTERNATIONAL MEDIA ACQUISITION CORP. TO PUBLICLY LIST ON THE NASDAQ
NEW YORK, April 9, 2025 /PRNewswire/ -- The Vietnamese ethanol production company, Vietnam Biofuels Development Joint Stock Company and its affiliates (together, "Vietnam Biofuels" or "VNB"), VCI Holdings Limited ("VCI" and together with VNB, the "VCI Biofuels Group") and International Media Acq...
2025-04-10 04:40
4352
Week's Top Stories
Most Reposted
Amorepacific Showcases Innovative Technologies at CES 2026
[Picked up by 289 media titles]
2026-01-05 12:14
Radisson Hotel Group Revives Bangkok Icon with Opening of Radisson Hotel Chateau de Bangkok
[Picked up by 280 media titles]
2026-01-06 10:45
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 280 media titles]
2026-01-01 10:00
Hyundai Motor Group Executive Chair Chung Presents 2026 Vision: Customer-Focused Transformation and AI-Driven Ecosystem Collaboration
[Picked up by 264 media titles]
2026-01-05 09:10
Pepsi & 7UP Team Up with Disney on Zootopia 2, Sparking Fresh Wave of Crossover Youthful Energy
[Picked up by 256 media titles]
2025-12-31 12:53
Most Read
China Daily Launches "China Bound" -- An English-Language Smart-Tourism Service Platform for International Travelers
2026-01-01 17:04
8287
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
2026-01-01 10:00
7391